Cardiff Oncology, Inc.

Equities

CRDF

US14147L1089

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:00:25 2024-07-16 EDT			5-day change	1st Jan Change
2.56 ^USD	+1.99%		+16.51%	+71.62%

07-01	Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Small Cap Comp Value Index	CI
07-01	Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Small Cap Completeness Index	CI

TROVAGENE, INC. : Other Events (form 8-K)

January 27, 2020 at 11:01 am

Item 8.01 Other Events.

On January 27, 2020, Trovagene, Inc. issued a press release announcing positive data from an ongoing Phase 1b/2 clinical trial of onvansertib plus FOLFIRI and Avastin® (bevacizumab) for second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC). A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Latest news about Cardiff Oncology, Inc.

Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Small Cap Comp Value Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Small Cap Completeness Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2000 Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000E Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000 Growth Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2500 Value Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Microcap Growth Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000 Value Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2000 Value Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000E Growth Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2000 Growth Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2000 Dynamic Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2500 Growth Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell Small Cap Comp Growth Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 2500 Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000 Index	06-30	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) added to Russell 3000E Value Index	06-30	CI
Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study	04-08	CI
HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating	03-06	MT
Sector Update: Health Care Stocks Rising Late Afternoon	03-01	MT
Sector Update: Health Care	03-01	MT
Cardiff Oncology Shares Jump, Discontinued Cancer Treatment Trial Shows Efficacy	03-01	MT
Piper Sandler Adjusts Price Target on Cardiff Oncology to $7 From $5, Maintains Overweight Rating	03-01	MT

Chart Cardiff Oncology, Inc.

Duration

Period

More charts

Company Profile

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cardiff Oncology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.51 USD

Average target price

9.833 USD

Spread / Average Target

+291.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CARDIFF ONCOLOGY, INC.	+71.62%	112M
MODERNA, INC.	+25.36%	46.56B
LONZA GROUP AG	+45.49%	41.67B
IQVIA HOLDINGS INC.	-0.41%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+34.40%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.83%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.27%	14.52B
MEDPACE HOLDINGS, INC.	+47.43%	13.74B
BIO-TECHNE CORPORATION	+1.76%	12.17B

Other Biotechnology & Medical Research